ArticleJournal of acquired immune deficiency syndromes (1999)2020
Trends in Time From HIV Diagnosis to First Viral Suppression Following Revised US HIV Treatment Guidelines, 2012-2017.
Article in Journal of acquired immune deficiency syndromes (1999), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Reducing time to differentiated service delivery for newly-diagnosed people living with HIV in Kigali, Rwanda: a pilot, unblinded, randomized controlled trial.BMC health services research · 2024Trial
- Developing a Toolkit to Support Dissemination and Implementation of the Red Carpet Entry Program.AIDS and behavior · 2026Article
- Assessing the Benefits of Rapid Start Antiretroviral Therapy for Newly Diagnosed People with HIV in the United States.Advances in therapy · 2025Article
- HIV Care Linkage and Initial Viral Suppression Among Persons Newly Diagnosed With HIV in North Carolina Before and After the Start of the COVID-19 Pandemic.American journal of public health · 2025Article
- Factors associated with viral load non-suppression among adults with HIV in Sughd region, Tajikistan: a retrospective cohort study.BMC infectious diseases · 2025Article
- Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data.AIDS research and therapy · 2025Article
- Staged HIV transmission and treatment in a dynamic model with long-term partnerships.Journal of mathematical biology · 2023Article
- Toward Ending the HIV Epidemic: Temporal Trends and Disparities in Early ART Initiation and Early Viral Suppression Among People Newly Entering HIV Care in the United States, 2012-2018.Open forum infectious diseases · 2022Article
- Article
- Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study.Annals of internal medicine · 2021Observational
- Vital Signs: Deaths Among Persons with Diagnosed HIV Infection, United States, 2010-2018.MMWR. Morbidity and mortality weekly report · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundSince 2012, treatment guidelines have recommended initiating antiretroviral therapy for all persons as soon as possible after HIV diagnosis, irrespective of CD4 counts. If clinicians adopted the treatment guidelines, a shortened interval between diagnosis and first viral suppression (Dx-to-VS) would be expected, with greater declines among those with CD4 counts ≥500 cells/µL at diagnosis.
methodsUsing the National HIV Surveillance System data, we examined Dx-to-VS intervals among persons aged ≥13 years with HIV infection diagnosed during 2012-2017. Analyses were stratified by the first CD4 count: CD4 ≥500 cells/µL, 200-499 cells/µL, <200 cells/µL, and no CD4 value reported within 3 months after diagnosis.
resultsDuring 2012-2017 in the 27 US jurisdictions with complete laboratory reporting, 138,759 HIV diagnoses occurred. The median Dx-to-VS interval shortened overall for persons with HIV diagnosed in 2012 vs. 2017 from 9 to 5 months, a 12.3% annual decrease (P < 0.001) and in all CD4 groups. In 2012, the Dx-to-VS interval was longer for persons with CD4 ≥500 cells/µL than 200-499 cells/µL and <200 cells/µL (median, 9, 7, and 6 months, respectively). By 2017, the median interval was 4 months for these groups, compared with 25 months for those without a CD4 value within 3 months after diagnosis.
conclusionDecreases in Dx-to-VS intervals across all CD4 groups with a greater decrease among those with CD4 ≥500 cells/µL are consistent with the implementation of treatment recommendations. The Dx-to-VS interval was longest among persons not linked to care within 3 months after diagnosis, underscoring the importance of addressing barriers to linkage to care for ending the HIV epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.